MAZE · Maze Therapeutics, Inc. · Stock research

Current Thesis

The leg on offer is unchanged in substance: a genetics-first kidney company with clinical proof-of-concept in APOL1-mediated kidney disease (AMKD), funded into 2029, trading at $27.18 (close of 2026-08-14) against published sell-side targets that start at $46. What changed since late July is the schedule. The 2026-08-11 second-quarter report moved MZE782's Phase 2 CIPheR topline in PKU to 2027 and pushed the MZE782 CKD Phase 2 initiation to H1 2027; the only company-controlled 2026 read left is HORIZON data across three cohorts of 10–15 patients, guided "late 2026 or early 2027." The pivotal for MZE829 is now dated H1 2027, subject to regulatory feedback. The narrative is maturing — the story is well known and the structure has held (price $27.68 on 2026-07-24 to $27.18 on 2026-08-14, three-month return +6.3%), but attention is moderating, RSI(14) is 38.3 and there is nothing on the tape to bid for until Q4 at the earliest. The distance to the 52-week high of $51.84 is -47.6%.

Bullish and bearish views on Maze Therapeutics, Inc.

The model's bull view on Maze Therapeutics, Inc. (MAZE), in brief: Broad-AMKD efficacy signal, 2026-03-25: MZE829 cut mean uACR 35.6% at week 12 across broad AMKD, with 61.8% in the severe-FSGS subgroup and 48.6% in non-diabetic AMKD; roughly half of patients hit a >30% reduction. The bear view: The 2026 calendar emptied at the print: MZE782 PKU topline is now 2027 and the CKD Phase 2 start H1 2027 (Q2 release, 2026-08-11), versus the mid-2026 PKU / H2-2026 CKD framing carried earlier in the year. Both cases follow in full.

Bull Case

• Broad-AMKD efficacy signal, 2026-03-25: MZE829 cut mean uACR 35.6% at week 12 across broad AMKD, with 61.8% in the severe-FSGS subgroup and 48.6% in non-diabetic AMKD; roughly half of patients hit a >30% reduction.
• Tolerability supports chronic oral dosing, 2026-03-25 topline: no serious adverse events and no severe treatment-related events across doses; headache and diarrhea most frequent.
• Balance sheet covers the pivotal: $494.9M in cash, cash equivalents and marketable securities at 2026-06-30, with runway guided into 2029 (Q2 release, 2026-08-11) — the H1 2027 pivotal start does not require a financing on the company's own guidance.
• The pivotal now has a date: H1 2027 initiation for MZE829, subject to regulatory feedback (Q2 release, 2026-08-11). Prior framing left the start open-ended.
• Second oral asset is dosing: MZE782 Phase 1 (2025-09-11) showed a 42-fold rise in urinary phenylalanine at 240mg BID across 112 subjects; the Phase 2 CIPheR trial in PKU is initiated and enrolling as of the Q2 report.
• Sell-side has not cut: BTIG reiterated Buy with a $46 target on 2026-08-12, the day after an EPS miss. Third-party compilations published 2026-08-15 put the average 12-month target at $66.00, with a high mark of $110, against the $27.18 close.

Bear Case

• The 2026 calendar emptied at the print: MZE782 PKU topline is now 2027 and the CKD Phase 2 start H1 2027 (Q2 release, 2026-08-11), versus the mid-2026 PKU / H2-2026 CKD framing carried earlier in the year. Two of the three near-term inflections moved right in one release.
• The surviving 2026 read is small: HORIZON's late-2026/early-2027 data covers three cohorts of 10–15 patients. Point estimates off cohorts that size carry wide intervals; a number below the March 35.6% does not by itself mean the drug failed, and a number above it does not confirm.
• Spend is scaling ahead of the pivotal: Q2 net loss $44.7M, or $(0.76) per share, against a $(0.73) consensus (2026-08-11); first-half R&D $69.1M vs $55.7M a year earlier, G&A $25.5M vs $16.2M.
• Class leader is ahead: Vertex's inaxaplin is in the Phase 3 AMPLITUDE portion with full enrollment guided H2 2026 and interim data early 2027 — a read that could define the AMKD standard before Maze's pivotal begins.

• The print produced no re-rating: an EPS miss on 2026-08-11 and a $46 reiteration on 2026-08-12 left the close at $27.18 on 2026-08-14, inside the July range.

Setup & Price Structure

• $27.18 close (2026-08-14) with RSI(14) at 38.3 — the July bounce has bled out without setting a new low. Three-month return +6.3%.
• The 2026-04 placement at $23.50 is the level the tape has traded above since the March data; it and the post-HORIZON consolidation are the same structure.
• 52-week high $51.84; the name sits 47.6% below it. There is no rising moving-average extension to fade here — the setup is range, not trend.
• Positioning observables, stated as observables: no earnings inside 30 days (Q2 landed 2026-08-11, next print ~2026-11-10 est.); RSI below 50 with price near mid-range argues against momentum crowding; the visible crowding is analyst-side, with targets spanning $46 to $110 against a $27.18 close; issuance at $23.50 in April and the 2026-07-01 insider sale at $29.90 are both supply into lifts.
• Float is thin at roughly 55.35M shares with light average volume — single prints can set a session's range, and gaps are the norm around data.

Catalyst Calendar (next 30 days)

• 2026-08-16 → 2026-09-15: no company-dated catalyst. The Q2 report (2026-08-11) is done and the blackout it created has closed; nothing scheduled replaces it inside the window.
• 2026-10-21 – 2026-10-25 — ASN Kidney Week, Denver. A data-detail venue where prior-year abstracts have been presented; historically incremental rather than a fresh binary.
• ~2026-11-10 (est.) — Q3 2026 report. Reconfirms or moves the HORIZON all-cohort window and the H1 2027 pivotal start.
• Late 2026 – early 2027 (guided) — HORIZON data across three 10–15 patient cohorts. The next real value inflection.
• H1 2027 (guided) — MZE829 pivotal initiation and MZE782 CKD Phase 2 initiation.

What Would Change Our Mind

The structure that matters is the April 2026 placement shelf at $23.50, which the tape has defended through the drawdown from $51.84; a weekly close below $23.50 removes it and leaves no reference between there and the January 2025 IPO price of $16. Separately, the case weakens without any price event if the HORIZON all-cohort data lands materially below the 35.6% mean uACR reduction reported 2026-03-25 or arrives without eGFR support, since the pivotal design leans on that surrogate; or if the ~November Q3 report moves the all-cohort read out of the late-2026/early-2027 window, which would make it three consecutive quarters of timelines sliding right. A positive Vertex inaxaplin interim in early 2027 with an accelerated-approval filing would compress the differentiation argument regardless of what MZE829 shows. On the other side, full-cohort data in hand with kidney-function support plus a regulator-agreed pivotal design would move the label back toward accelerating — that combination is the condition, not the calendar.

Correlation Notes

• Beta comes from the small/mid-cap clinical biotech complex (XBI-type exposure): no revenue, no approved product, so valuation is duration against rates and risk appetite rather than earnings.
• Vertex is the single largest external driver — AMPLITUDE enrollment and interim commentary read directly onto Maze's broad-AMKD positioning, in both directions.
• The wider precision-nephrology group shares regulatory precedent on proteinuria-based accelerated approval; agency language in any peer kidney approval or complete response is a cross-read on the H1 2027 pivotal design.
• Idiosyncratic risk dominates: the March 2026 and forthcoming HORIZON prints move this name independently of index direction.